{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:28:28Z","timestamp":1786516108871,"version":"build-2736575974"},"reference-count":21,"publisher":"IOP Publishing","issue":"4","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/publishingsupport.iopscience.iop.org\/iop-standard\/v1"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":11,"URL":"https:\/\/iopscience.iop.org\/info\/page\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/publishingsupport.iopscience.iop.org\/questions\/alternative-author-rights-policies\/"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/publishingsupport.iopscience.iop.org\/questions\/alternative-author-rights-policies\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82203885"],"award-info":[{"award-number":["82203885"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jilin Province Science and Technology Development Plan","award":["YDZJ202201ZYTS077"],"award-info":[{"award-number":["YDZJ202201ZYTS077"]}]}],"content-domain":{"domain":["iopscience.iop.org"],"crossmark-restriction":false},"short-container-title":["Biomed. Mater."],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Low immunogenicity and a prevailing immunosuppressive tumor microenvironment (TME) remain major bottlenecks for ovarian cancer (OC) immunotherapy. While platinum-based chemotherapy can trigger antitumor immunity via immunogenic cell death (ICD), its clinical efficacy is often hampered by the intrinsic immunosuppressive milieu and insufficient drug accumulation at the tumor site following systemic administration. To address these challenges, we fabricated a syringeable hyaluronic acid-based hydrogel co-loaded with Cisplatin (CDDP) and STING agonist MSA-2 (CDDP\/MSA-2@Gel) for enhanced localized chemoimmunotherapy. The sustained local release of CDDP and MSA-2 synergistically boost stimulator of interferon genes (STING) pathway activation, thereby eliciting potent type-I-IFN-driven systemic antitumor immune responses and alleviating the immunosuppressive TME.\n                    <jats:italic>In vivo<\/jats:italic>\n                    studies demonstrated that CDDP\/MSA-2@Gel treatment significantly inhibits tumor growth in murine OC models without systemic toxicity. Collectively, our designed CDDP\/MSA-2@Gel represents a safe and potent strategy for enhanced synergistic chemoimmunotherapy, offering significant potential for clinical translation in the treatment of OC.\n                  <\/jats:p>","DOI":"10.1088\/1748-605x\/ae8b4c","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:54:28Z","timestamp":1784156068000},"page":"045034","update-policy":"https:\/\/doi.org\/10.1088\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Syringeable hyaluronic acid-based hydrogel co-loaded with cisplatin and MSA-2 for enhanced ovarian cancer chemoimmunotherapy"],"prefix":"10.1088","volume":"21","author":[{"given":"Zhengfei","family":"Sun","sequence":"first","affiliation":[{"name":"Puyang People\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehua","family":"Wei","sequence":"additional","affiliation":[{"name":"Puyang People\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0664-656X","authenticated-orcid":true,"given":"Guofeng","family":"Ji","sequence":"additional","affiliation":[{"name":"Capital Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"266","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"bmmae8b4cbib1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","type":"journal-article","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"bmmae8b4cbib2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114205","type":"journal-article","article-title":"Therapeutic strategies to overcome cisplatin resistance in ovarian cancer","volume":"232","author":"Song","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"bmmae8b4cbib3","doi-asserted-by":"publisher","first-page":"18691","DOI":"10.1021\/acsami.9b02346","type":"journal-article","article-title":"Light-activatable prodrug and AIEgen copolymer nanoparticle for dual-drug monitoring and combination therapy","volume":"11","author":"Wu","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"bmmae8b4cbib4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","type":"journal-article","article-title":"Ovarian cancer: an integrated review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"bmmae8b4cbib5","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41401-020-0448-9","type":"journal-article","article-title":"Cancer nanomedicine meets immunotherapy: opportunities and challenges","volume":"41","author":"Sun","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"bmmae8b4cbib6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310859","type":"journal-article","article-title":"Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors","volume":"24","author":"Paw\u0142owska","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"bmmae8b4cbib7","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2447403","type":"journal-article","article-title":"The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy","volume":"57","author":"Li","year":"2025","journal-title":"Ann. Med."},{"key":"bmmae8b4cbib8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","type":"journal-article","article-title":"Can advanced-stage ovarian cancer be cured?, nature reviews","volume":"13","author":"Narod","year":"2016","journal-title":"Clin. Oncol."},{"key":"bmmae8b4cbib9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S0140-6736(21)00128-8","type":"journal-article","article-title":"A source of hope for platinum-resistant ovarian cancer?","volume":"397","author":"Blagden","year":"2021","journal-title":"Lancet"},{"key":"bmmae8b4cbib10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.3045","type":"journal-article","article-title":"Dual role of immunomodulation by anticancer chemotherapy","volume":"19","author":"Shurin","year":"2013","journal-title":"Nat. Med."},{"key":"bmmae8b4cbib11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-025-01691-5","type":"journal-article","article-title":"The cGAS\u2013STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications","volume":"18","author":"Shen","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"bmmae8b4cbib12","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nri3921","type":"journal-article","article-title":"STING: infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"bmmae8b4cbib13","doi-asserted-by":"publisher","first-page":"eaba6098","DOI":"10.1126\/science.aba6098","type":"journal-article","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"Pan","year":"2020","journal-title":"Science"},{"key":"bmmae8b4cbib14","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202110588","type":"journal-article","article-title":"A 2D nanoradiosensitizer enhances radiotherapy and delivers STING agonists to potentiate cancer immunotherapy","volume":"34","author":"Luo","year":"2022","journal-title":"Adv. Mater."},{"key":"bmmae8b4cbib15","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202509309","type":"journal-article","article-title":"Hyaluronic acid hydrogel implants for sustained release of oxaliplatin and resiquimod to prevent hepatocellular carcinoma recurrence post-radiofrequency ablation","volume":"12","author":"Shan","year":"2025","journal-title":"Adv. Sci."},{"key":"bmmae8b4cbib16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0022-1759(02)00013-3","type":"journal-article","article-title":"A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells","volume":"262","author":"Son","year":"2002","journal-title":"J. Immunol. Methods"},{"key":"bmmae8b4cbib17","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405935","type":"journal-article","article-title":"Minimally invasive injectable gel for local immunotherapy of liver and gastric cancer","volume":"11","author":"Si","year":"2024","journal-title":"Adv. Sci."},{"key":"bmmae8b4cbib18","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1021\/acsnano.3c08376","type":"journal-article","article-title":"Injectable nano-in-gel vaccine for spatial and temporal control of vaccine kinetics and breast cancer postsurgical therapy","volume":"18","author":"Liu","year":"2024","journal-title":"ACS Nano"},{"key":"bmmae8b4cbib19","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.1038\/s41467-022-33301-0","type":"journal-article","article-title":"A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"bmmae8b4cbib20","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202300854","type":"journal-article","article-title":"Sono-driven STING activation using semiconducting polymeric nanoagonists for precision sono-immunotherapy of head and neck squamous cell carcinoma","volume":"35","author":"Jiang","year":"2023","journal-title":"Adv. Mater."},{"key":"bmmae8b4cbib21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12943-020-01250-1","type":"journal-article","article-title":"Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy","volume":"19","author":"Zheng","year":"2020","journal-title":"Mol. Cancer"}],"container-title":["Biomedical Materials"],"original-title":[],"link":[{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1748-605X\/ae8b4c","content-type":"text\/html","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1748-605X\/ae8b4c\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1748-605X\/ae8b4c","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1748-605X\/ae8b4c\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1748-605X\/ae8b4c\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1748-605X\/ae8b4c\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1748-605X\/ae8b4c\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"similarity-checking"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1748-605X\/ae8b4c\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:38:58Z","timestamp":1786513138000},"score":1,"resource":{"primary":{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1748-605X\/ae8b4c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,12]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1088\/1748-605x\/ae8b4c","relation":{},"ISSN":["1748-6041","1748-605X"],"issn-type":[{"value":"1748-6041","type":"print"},{"value":"1748-605X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"Syringeable hyaluronic acid-based hydrogel co-loaded with cisplatin and MSA-2 for enhanced ovarian cancer chemoimmunotherapy","name":"article_title","label":"Article Title"},{"value":"Biomedical Materials","name":"journal_title","label":"Journal Title"},{"value":"paper","name":"article_type","label":"Article Type"},{"value":"\u00a9 2026 IOP Publishing Ltd. All rights, including for text and data mining, AI training, and similar technologies, are reserved.","name":"copyright_information","label":"Copyright Information"},{"value":"2026-03-30","name":"date_received","label":"Date Received","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2026-07-15","name":"date_accepted","label":"Date Accepted","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2026-08-12","name":"date_epub","label":"Online publication date","group":{"name":"publication_dates","label":"Publication dates"}}]}}